专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US11857714B2 Systems and methods for monitoring and controlling fluid balance during a biological fluid procedure 有权
公开(公告)号：US11857714B2
公开(公告)日：2024-01-02
申请号：US18100023
申请日：2023-01-23
申请人： Fenwal, Inc.
发明人： Zahra R Ali , Lan T. Nguyen
IPC分类号： A61M1/36 , A61M1/38 , A61M1/02
CPC分类号： A61M1/3607 , A61M1/0209 , A61M1/361 , A61M1/3643 , A61M1/3672 , A61M1/3683 , A61M1/3693 , A61M1/3696 , A61M1/38 , A61M2202/0092 , A61M2202/0407 , A61M2202/0413 , A61M2202/0415 , A61M2202/0429 , A61M2202/0439 , A61M2202/0443 , A61M2205/3386 , A61M2205/50 , A61M2230/005 , A61M2230/207
摘要： Described is a method for controlling fluid volume balance. A controller is configured with a first set of inputs comprising a hematocrit, a total blood volume, and an ACD ratio. A maximum extracorporeal RBC amount during the procedure is estimated based on the first set of inputs. A fluid circuit is primed with a priming fluid. Whole blood is drawn from a blood source and separated into a RBC component, a target cell component, and a plasma component. The target cell component is directed to a product container. The product container comprising the target cell component is treated. A treated target cell component, a portion of the RBC component remaining in the fluid circuit, and/or a portion of the plasma component remaining in the fluid circuit are returned to the blood source. A first response action is provided if the maximum extracorporeal RBC amount estimated is above a programmed limit.

2. 发明授权

US11666693B2 Automated method for leukocyte collection from whole blood 有权
公开(公告)号：US11666693B2
公开(公告)日：2023-06-06
申请号：US16324178
申请日：2017-08-17
申请人： Fresenius Kabi Deutschland
发明人： Heike Mitschulat , Michael Brinkmann
IPC分类号： A61M1/36 , A61M1/38 , A61M1/02 , B04B5/04 , B04B11/02 , B04B13/00
CPC分类号： A61M1/3696 , A61M1/0209 , A61M1/0272 , A61M1/382 , B04B5/0442 , B04B11/02 , A61M2202/0407 , A61M2202/0437 , A61M2202/0439 , A61M2205/331 , A61M2205/3303 , A61M2205/3331 , B04B2013/006
摘要： The present invention relates to a method for separating lymphocytes and/or stem cells from whole blood in an automated blood separation system, wherein the quality of the collected lymphocytes and/or stem cells fractions is increased and the cell collection procedure is further automated by use of an optical sensor comprised in a detector device to measure turbidity and colour in the claimed method and in a cell separator, which can be used to perform the claimed method. The method of the invention is particularly useful to collect lymphocytes and/or stem cells fractions from whole blood, wherein the contamination of the collected cell fractions by platelets, red blood cells and granulocytes is reduced.

3. 发明申请

US20120277652A1 Stem Cell Immune Modulation Methods of Use and Apparatus 有权
标题翻译：干细胞免疫调节方法和装置
公开(公告)号：US20120277652A1
公开(公告)日：2012-11-01
申请号：US13514694
申请日：2010-12-08
申请人： Yong Zhao
发明人： Yong Zhao
IPC分类号： A61M1/16 , C12N5/0783 , C12M3/00
CPC分类号： A61M1/3489 , A61K2035/122 , A61M1/3472 , A61M2202/0407 , C12M25/08 , C12M35/08 , C12N5/0634 , C12N2502/11
摘要： Methods and apparatus are disclosed co-culturing stem cells with mononuclear cells and/or lymphocytes to modulate their function. The invention also discloses the use of stem cells to educate autoreactive immune cells as a mechanism to treat autoimmune diseases and immune disorder-related diseases, such as diabetes. In one aspect of the invention, bioreactors are disclosed closed for modulating lymphocytes and suppressing autoreactive T cells. The bioreactors can include a chamber having at least one positively charged and/or hydrophobic substrate surface, a population of stem cells attached to the substrate surface, an inlet conduit for introducing lymphocytes into the chamber, and an outlet conduit for extracting treated lymphocytes following co-culturing with the stem cells.
摘要翻译：公开了与单核细胞和/或淋巴细胞共培养干细胞以调节其功能的方法和装置。本发明还公开了使用干细胞来教育自身免疫细胞作为治疗自身免疫疾病和免疫疾病相关疾病如糖尿病的机制。在本发明的一个方面，公开了用于调节淋巴细胞和抑制自身反应性T细胞的生物反应器。生物反应器可以包括具有至少一个带正电荷和/或疏水底物表面的腔室，连接到基底表面的干细胞群，用于将淋巴细胞引入腔室的入口导管，以及用于在下列处理之后提取处理的淋巴细胞的出口导管用干细胞培养。

4. 发明授权

US5456845A Method for separating a blood material into blood component products 失效
标题翻译：将血液物质分离成血液成分制品的方法
公开(公告)号：US5456845A
公开(公告)日：1995-10-10
申请号：US199511
申请日：1994-02-22
申请人： Takao Nishimura , Kenji Kobayashi , Junko Sato
发明人： Takao Nishimura , Kenji Kobayashi , Junko Sato
IPC分类号： A61M1/22 , A61M1/02 , A61M1/34 , A61M1/36 , B04B5/04 , B01D21/26 , B01D35/02
CPC分类号： B04B5/0428 , A61M1/0209 , A61M1/0227 , A61M1/3693 , A61M2202/0407
摘要： Disclosed is a method for separating a blood material into leukocyte-removed blood component products, which comprises providing a multiple blood bag system comprising a primary bag containing a blood material, a leukocyte-removing filter device comprising a flat casing, and at least one satellite bag, and centrifuging the blood material using a centrifuge cup having the multiple blood bag system accommodated therein, to thereby separate the blood material into blood components, wherein the centrifugation is performed with the filter device being held by a filter device holder having a substantially flat dimension which is disposed in a centrifuge cup so as to extend in a direction perpendicular to an inner bottom floor of the centrifuge cup, and wherein the filter device holder has a recess and the filter device is received by the recess in a manner such that a flat surface of the flat casing of the filter device is perpendicular to the inner bottom floor of the centrifuge cup. By the method of the present invention, not only can the accommodation of a multiple blood bag system into a centrifuge cup be readily performed without any additional cumbersome operations, but also the danger of damaging the filter device and the blood bags is extremely reduced or eliminated.
摘要翻译：公开了一种将血液物质分离为去除白细胞的血液成分产物的方法，其包括提供多血袋系统，其包含含有血液物质的初级袋，包含平坦壳体的白细胞除去过滤器装置和至少一个卫星使用容纳有多个血液袋系统的离心杯离心血液材料，从而将血液物质分离成血液成分，其中，过滤装置由具有基本平坦的过滤器装置保持器其设置在离心杯中，以便在垂直于离心杯的内底面的方向上延伸，并且其中过滤器装置保持器具有凹部，并且过滤器装置以凹槽的方式被接收，使得过滤装置的扁平壳体的平坦表面垂直于离心杯的内底层。通过本发明的方法，不仅可以容易地进行将多个血袋系统容纳到离心杯中，而且不会有任何额外的繁琐的操作，而且极大地减少或消除了过滤装置和血袋的损坏危险。

5. 发明授权

US4330410A Separation of leukocytes from leukocyte-containing suspension by filtration 失效
标题翻译：通过过滤从含白细胞的悬浮液中分离白细胞
公开(公告)号：US4330410A
公开(公告)日：1982-05-18
申请号：US170384
申请日：1980-07-21
申请人： Yoshinori Takenaka , Nobuaki Tsuda , Toru Kuroda
发明人： Yoshinori Takenaka , Nobuaki Tsuda , Toru Kuroda
IPC分类号： B01D29/00 , B01D29/01 , B01D37/00
CPC分类号： B01D29/01 , A61M2202/0407
摘要： Leukocytes are advantageously separated from blood or other leukocyte-containing suspensions by causing the leukocyte-containing suspensions to flow through a filter unit comprising a container provided with inlet and outlet conduit means and with a mass of fibers packed therein. The mass of fibers is characterized as possessing a bulk density of from 0.02 to 0.40 gram/cubic centimeter, and each of the fibers is characterized as having an average diameter of from 3 to 10 microns. The fibers to be used are selected from synthetic fibers, semi-synthetic fibers, regenerated fibers and natural proteinaceous fibers.
摘要翻译：通过使含有白细胞的悬浮液通过包含设置有入口和出口导管装置的容器的过滤器单元以及填充有纤维素的纤维，白细胞有利地与血液或其它含白细胞的悬浮液分离。纤维质量的特征在于具有0.02至0.40克/立方厘米的堆积密度，并且每种纤维的特征在于其平均直径为3至10微米。所使用的纤维选自合成纤维，半合成纤维，再生纤维和天然蛋白质纤维。

6. 发明公开

US20230149615A1 Systems And Methods For Monitoring And Controlling Fluid Balance During A Biological Fluid Procedure 审中-公开
公开(公告)号：US20230149615A1
公开(公告)日：2023-05-18
申请号：US18100023
申请日：2023-01-23
申请人： Fenwal, Inc.
发明人： Zahra R. Ali , Lan T. Nguyen
IPC分类号： A61M1/36 , A61M1/38 , A61M1/02
CPC分类号： A61M1/3607 , A61M1/38 , A61M1/0209 , A61M1/361 , A61M1/3643 , A61M1/3672 , A61M1/3683 , A61M1/3693 , A61M1/3696 , A61M2202/0092 , A61M2202/0407 , A61M2202/0413 , A61M2202/0415 , A61M2202/0429 , A61M2202/0439 , A61M2202/0443 , A61M2205/50 , A61M2205/3386 , A61M2230/005 , A61M2230/207
摘要： Described is a method for controlling fluid volume balance. A controller is configured with a first set of inputs comprising a hematocrit, a total blood volume, and an ACD ratio. A maximum extracorporeal RBC amount during the procedure is estimated based on the first set of inputs. A fluid circuit is primed with a priming fluid. Whole blood is drawn from a blood source and separated into a RBC component, a target cell component, and a plasma component. The target cell component is directed to a product container. The product container comprising the target cell component is treated. A treated target cell component, a portion of the RBC component remaining in the fluid circuit, and/or a portion of the plasma component remaining in the fluid circuit are returned to the blood source. A first response action is provided if the maximum extracorporeal RBC amount estimated is above a programmed limit.

7. 发明授权

US09278170B2 Carbon and its use in blood cleansing applications 有权
标题翻译：碳及其在血液清洁应用中的应用
公开(公告)号：US09278170B2
公开(公告)日：2016-03-08
申请号：US13513340
申请日：2010-12-09
申请人： Stephen Robert Tennison , Oleksandr Prokopovyeh Kozynchenko , Anthony Paul Rawlinson , Gary James Phillips , Carol Angela Howell , Susan Rachel Sandeman , Sergey Victorovich Mikhalovsky
发明人： Stephen Robert Tennison , Oleksandr Prokopovyeh Kozynchenko , Anthony Paul Rawlinson , Gary James Phillips , Carol Angela Howell , Susan Rachel Sandeman , Sergey Victorovich Mikhalovsky
IPC分类号： A61M37/00 , A61M1/34 , A61M1/36
CPC分类号： A61M1/34 , A61M1/3486 , A61M1/3496 , A61M1/362 , A61M2202/0057 , A61M2202/0407 , A61M2202/07 , A61M2202/08 , A61M2202/203
摘要： Whole blood is treated extracorporeally to remove substances contrary to health using mesoporous/microporous or macroporopus/microporous carbon in the form of beads or a channel monolith. The carbon may be the result of carbonizing a mesoporous or macroporous phenolic resin. Substances contrary to health include externally introduced toxins such as bacterially derived staphylococcus enterotoxins A, B, TSST-1 or autologous, biologically active molecules with harmful, systemic effects when their activity is excessive or unregulated. Examples include the removal of inappropriate amounts of pro- or anti-inflammatory molecules and toxic mediators of systemic inflammatory response syndrome related to sepsis, cardio-pulmonary by-pass surgery, ischaemic reperfusion injury; the removal of larger molecular weight and protein bound uremic toxins related to kidney and hepatic toxins related to liver failure and the removal of toxins relevant to biological and chemical warfare.
摘要翻译：使用球形或通道整体形式的介孔/微孔或大孔/微孔碳体外处理全血以除去与健康相反的物质。碳可以是中孔或大孔酚醛树脂碳化的结果。与健康相反的物质包括外来引入的毒素，如细菌衍生的葡萄球菌肠毒素A，B，TSST-1或自身的生物活性分子，当其活性过度或不受调节时，具有有害的全身作用。实例包括去除与脓毒症，心肺旁路手术，缺血再灌注损伤相关的全身炎症反应综合征的不利量的促炎或抗炎分子和毒性介质; 去除与肝衰竭有关的肾脏和肝脏毒素相关的较大分子量和蛋白质结合的尿毒症毒素以及与生物和化学战争相关的毒素的去除。

8. 发明授权

US4411792A Lymph filtration system 失效
标题翻译：淋巴滤过系统
公开(公告)号：US4411792A
公开(公告)日：1983-10-25
申请号：US291175
申请日：1981-08-10
申请人： Albert L. Babb
发明人： Albert L. Babb
IPC分类号： A61M1/34 , A61M1/36 , B01D63/08 , B01D31/00 , B01D13/00
CPC分类号： B01D63/087 , A61M1/3496 , A61M1/3603 , A61M2202/0405 , A61M2202/0407 , A61M2205/7554 , A61M2206/12
摘要： A lymphapheresis or lymph filtration system is disclosed for removing lymph from a patient, separating the lymph into a liquid fraction and a cellular component fraction and returning the liquid fraction to the patient. The system includes an input pump to pump lymph from the patient into a filtration cell having a membrane which filters the lymph into fractions. The liquid fraction is removed from the cell by a reversible pump and is returned to the patient. As the membrane becomes plugged the reversible pump is reversed to backflush the membrane to return it to a high filtration rate. The cellular component fraction which includes lymphocytes is disposed of.
摘要翻译：公开了一种用于从患者中除去淋巴液的淋巴细胞过滤或淋巴过滤系统，将淋巴液分离成液体部分和细胞组分级分并将液体馏分返回给患者。该系统包括一个输入泵，将来自患者的淋巴液泵入具有将淋巴过滤成部分的膜的过滤细胞。液体部分通过可逆泵从细胞中除去并返回到患者体内。当膜被堵塞时，可逆泵被反向以反冲膜以将其返回到高过滤速率。处理包括淋巴细胞的细胞组分级分。

9. 发明申请

US20170049951A1 METHODS AND SYSTEMS FOR PROCESSING AND WASHING A PHOTOPHERESIS MONONUCLEAR CELL PRODUCT 审中-公开
标题翻译：加工和洗涤光聚合单核细胞产物的方法和系统
公开(公告)号：US20170049951A1
公开(公告)日：2017-02-23
申请号：US14828226
申请日：2015-08-17
申请人： Fenwal, Inc.
发明人： Tanima Jahan Abedin , Katherine N. Radwanski , Kyungyoon Min
IPC分类号： A61M1/36 , A61K35/14 , A61K41/00
CPC分类号： A61M1/3693 , A61K35/14 , A61K41/0057 , A61M1/0209 , A61M1/3496 , A61M1/3683 , A61M1/3686 , A61M1/3696 , A61M1/38 , A61M2202/0407 , A61M2202/0439 , A61M2205/12 , A61M2205/128
摘要： Methods and systems for the treatment and post-treatment processing of a mononuclear cell product are disclosed. The methods and systems include and provide for the separation of excess conditioning fluid and unbound treating agent prior to return of said treated mononuclear cell product to a patient.
摘要翻译：公开了用于单核细胞产物的治疗和后处理加工的方法和系统。所述方法和系统包括并提供在将所述经处理的单核细胞产物返回给患者之前分离过量调理液和未结合的处理剂。

10. 发明申请

US20130072845A1 CARBON AND ITS USE IN BLOOD CLEANSING APPLICATIONS 有权
标题翻译：碳及其在血液清洁应用中的用途
公开(公告)号：US20130072845A1
公开(公告)日：2013-03-21
申请号：US13513340
申请日：2010-12-09
申请人： Stephen Robert Tennison , Oleksandr Prokopovyeh Kozynchenko , Anthony Paul Rawlinson , Gary James Phillips , Carol Angela Howell , Susan Rachel Sandeman , Sergey Victorovich Mikhalovsky
发明人： Stephen Robert Tennison , Oleksandr Prokopovyeh Kozynchenko , Anthony Paul Rawlinson , Gary James Phillips , Carol Angela Howell , Susan Rachel Sandeman , Sergey Victorovich Mikhalovsky
IPC分类号： A61M1/34
CPC分类号： A61M1/34 , A61M1/3486 , A61M1/3496 , A61M1/362 , A61M2202/0057 , A61M2202/0407 , A61M2202/07 , A61M2202/08 , A61M2202/203
摘要： Whole blood is treated extracorporeally to remove substances contrary to health using mesoporous/microporous or macroporopus/microporous carbon in the form of beads or a channel monolith. The carbon may be the result of carbonising a mesoporous or macroporous phenolic resin. Substances contrary to health include externally introduced toxins such as bacterially derived staphylococcus enterotoxins A, B, TSST-1 or autologous, biologically active molecules with harmful, systemic effects when their activity is excessive or unregulated. Examples include the removal of inappropriate amounts of pro- or anti-inflammatory molecules and toxic mediators of systemic inflammatory response syndrome related to sepsis, cardio-pulmonary by-pass surgery, ischaemic reperfusioninjury; the removal of larger molecular weight and protein bound uremic toxins related to kidney and hepatic toxins related to liver failure and the removal of toxins relevant to biological and chemical warfare.
摘要翻译：使用球形或通道整体形式的介孔/微孔或大孔/微孔碳体外处理全血以除去与健康相反的物质。碳可能是中孔或大孔酚醛树脂碳化的结果。与健康相反的物质包括外来引入的毒素，如细菌衍生的葡萄球菌肠毒素A，B，TSST-1或自身的生物活性分子，当其活性过度或不受调节时，具有有害的全身作用。实例包括去除与脓毒症，心肺旁路手术，缺血性再灌注损伤有关的全身炎症反应综合征的不利量的促炎或抗炎分子和毒性介质; 去除与肝衰竭有关的肾脏和肝脏毒素相关的较大分子量和蛋白质结合的尿毒症毒素以及与生物和化学战争相关的毒素的去除。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式